In this review we will outline an approach to sequencing new therapies for metastatic castration-resistant prostate cancer (CRPC), with particular attention paid to the biology of CRPC.
Michael Hurwitz, MD, PhD
Advertisement
Articles by Michael Hurwitz, MD, PhD
Advertisement
Latest Updated Articles
Sequencing of Agents for Castration-Resistant Prostate CancerPublished: November 15th 2013 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
3
SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC
4
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
5
